|
Advisory Panel Vote on Pfizer’s Prevnar-13 Could Spell Trouble for Merck Vaccine
Pfizer is positioned to take a big bite out of Merck’s share of the adult pneumonia vaccine market following an FDA advisory panel’s approval recommendation for Prevnar-13.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives